A recent single-arm, phase II trial regarding pembrolizumab for the treatment of metastatic TNBC and hormone receptor-positive/HER2-negative endocrine-refractory BC demonstrated that pembrolizumab dose not significantly improve the median PFS compared with historic controls (8). This evidence concerns the gene ERBB2 and breast cancer.